Lilly’s Zyprexa Protection Strategy: Stress Efficacy, Institutional Market
This article was originally published in The Pink Sheet Daily
Executive Summary
With more than $5 billion operating cash flow, firm is looking for promising in-licensing candidates, CEO Lechleiter says.